644 related articles for article (PubMed ID: 23834232)
1. Pregnancy and newborn outcome of mothers with inflammatory bowel diseases exposed to anti-TNF-α therapy during pregnancy: three-center study.
Bortlik M; Machkova N; Duricova D; Malickova K; Hrdlicka L; Lukas M; Kohout P; Shonova O; Lukas M
Scand J Gastroenterol; 2013 Aug; 48(8):951-8. PubMed ID: 23834232
[TBL] [Abstract][Full Text] [Related]
2. Effects of discontinuing anti-tumor necrosis factor therapy during pregnancy on the course of inflammatory bowel disease and neonatal exposure.
Zelinkova Z; van der Ent C; Bruin KF; van Baalen O; Vermeulen HG; Smalbraak HJ; Ouwendijk RJ; Hoek AC; van der Werf SD; Kuipers EJ; van der Woude CJ;
Clin Gastroenterol Hepatol; 2013 Mar; 11(3):318-21. PubMed ID: 23103819
[TBL] [Abstract][Full Text] [Related]
3. Birth outcome in women with ulcerative colitis and Crohn's disease, and pharmacoepidemiological aspects of anti-inflammatory drug therapy.
Nørgård BM
Dan Med Bull; 2011 Dec; 58(12):B4360. PubMed ID: 22142578
[TBL] [Abstract][Full Text] [Related]
4. Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy.
Schnitzler F; Fidder H; Ferrante M; Ballet V; Noman M; Van Assche G; Spitz B; Hoffman I; Van Steen K; Vermeire S; Rutgeerts P
Inflamm Bowel Dis; 2011 Sep; 17(9):1846-54. PubMed ID: 21830263
[TBL] [Abstract][Full Text] [Related]
5. High intra-uterine exposure to infliximab following maternal anti-TNF treatment during pregnancy.
Zelinkova Z; de Haar C; de Ridder L; Pierik MJ; Kuipers EJ; Peppelenbosch MP; van der Woude CJ
Aliment Pharmacol Ther; 2011 May; 33(9):1053-8. PubMed ID: 21366638
[TBL] [Abstract][Full Text] [Related]
6. Safety of thiopurines and anti-TNF-α drugs during pregnancy in patients with inflammatory bowel disease.
Casanova MJ; Chaparro M; Domènech E; Barreiro-de Acosta M; Bermejo F; Iglesias E; Gomollón F; Rodrigo L; Calvet X; Esteve M; García-Planella E; García-López S; Taxonera C; Calvo M; López M; Ginard D; Gómez-García M; Garrido E; Pérez-Calle JL; Beltrán B; Piqueras M; Saro C; Botella B; Dueñas C; Ponferrada A; Mañosa M; García-Sánchez V; Maté J; Gisbert JP
Am J Gastroenterol; 2013 Mar; 108(3):433-40. PubMed ID: 23318480
[TBL] [Abstract][Full Text] [Related]
7. Development of an algorithm incorporating pharmacokinetics of adalimumab in inflammatory bowel diseases.
Roblin X; Rinaudo M; Del Tedesco E; Phelip JM; Genin C; Peyrin-Biroulet L; Paul S
Am J Gastroenterol; 2014 Aug; 109(8):1250-6. PubMed ID: 24913041
[TBL] [Abstract][Full Text] [Related]
8. Anti-TNF Levels in Cord Blood at Birth are Associated with Anti-TNF Type.
Kanis SL; de Lima-Karagiannis A; van der Ent C; Rizopoulos D; van der Woude CJ
J Crohns Colitis; 2018 Jul; 12(8):939-947. PubMed ID: 29771301
[TBL] [Abstract][Full Text] [Related]
9. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: pregnancy and pediatrics.
Mahadevan U; Cucchiara S; Hyams JS; Steinwurz F; Nuti F; Travis SP; Sandborn WJ; Colombel JF
Am J Gastroenterol; 2011 Feb; 106(2):214-23; quiz 224. PubMed ID: 21157441
[TBL] [Abstract][Full Text] [Related]
10. Serum Concentration of Anti-TNF Antibodies, Adverse Effects and Quality of Life in Patients with Inflammatory Bowel Disease in Remission on Maintenance Treatment.
Brandse JF; Vos LM; Jansen J; Schakel T; Ponsioen CI; van den Brink GR; D'Haens GR; Löwenberg M
J Crohns Colitis; 2015 Nov; 9(11):973-81. PubMed ID: 26116557
[TBL] [Abstract][Full Text] [Related]
11. Mucosal healing in pediatric Crohn's disease after anti-TNF therapy: a long-term experience at a single center.
Nobile S; Gionchetti P; Rizzello F; Calabrese C; Campieri M
Eur J Gastroenterol Hepatol; 2014 Apr; 26(4):458-65. PubMed ID: 24445727
[TBL] [Abstract][Full Text] [Related]
12. Pregnancy outcome in patients with inflammatory bowel disease treated with thiopurines: cohort from the CESAME Study.
Coelho J; Beaugerie L; Colombel JF; Hébuterne X; Lerebours E; Lémann M; Baumer P; Cosnes J; Bourreille A; Gendre JP; Seksik P; Blain A; Metman EH; Nisard A; Cadiot G; Veyrac M; Coffin B; Dray X; Carrat F; Marteau P;
Gut; 2011 Feb; 60(2):198-203. PubMed ID: 21115547
[TBL] [Abstract][Full Text] [Related]
13. Infliximab, adalimumab and vedolizumab concentrations across pregnancy and vedolizumab concentrations in infants following intrauterine exposure.
Flanagan E; Gibson PR; Wright EK; Moore GT; Sparrow MP; Connell W; Kamm MA; Begun J; Christensen B; De Cruz P; Shelton E; Dowling D; Andrews JM; Brown SJ; Niewiadomski O; Ward MG; Rosella O; Rosella G; Kiburg KV; Ross AL; Bell SJ;
Aliment Pharmacol Ther; 2020 Nov; 52(10):1551-1562. PubMed ID: 32981127
[TBL] [Abstract][Full Text] [Related]
14. Is safety infliximb during pregnancy in patients with inflammatory bowel disease?
Argüelles-Arias F; Castro-Laria L; Barreiro-de Acosta M; García-Sánchez MV; Guerrero-Jiménez P; Gómez-García MR; Cordero-Ruiz P; Iglesias-Flores E; Gómez-Camacho F; Domínguez-Muñoz EJ; Herrerías-Gutiérrez JM
Rev Esp Enferm Dig; 2012 Feb; 104(2):59-64. PubMed ID: 22372798
[TBL] [Abstract][Full Text] [Related]
15. Concentrations of Adalimumab and Infliximab in Mothers and Newborns, and Effects on Infection.
Julsgaard M; Christensen LA; Gibson PR; Gearry RB; Fallingborg J; Hvas CL; Bibby BM; Uldbjerg N; Connell WR; Rosella O; Grosen A; Brown SJ; Kjeldsen J; Wildt S; Svenningsen L; Sparrow MP; Walsh A; Connor SJ; Radford-Smith G; Lawrance IC; Andrews JM; Ellard K; Bell SJ
Gastroenterology; 2016 Jul; 151(1):110-9. PubMed ID: 27063728
[TBL] [Abstract][Full Text] [Related]
16. Exposure to Infliximab During Pregnancy: Post-Marketing Experience.
Geldhof A; Slater J; Clark M; Chandran U; Coppola D
Drug Saf; 2020 Feb; 43(2):147-161. PubMed ID: 31677004
[TBL] [Abstract][Full Text] [Related]
17. Safety of anti-TNF therapy in inflammatory bowel disease during pregnancy.
Khan N; Asim H; Lichtenstein GR
Expert Opin Drug Saf; 2014 Dec; 13(12):1699-708. PubMed ID: 25406728
[TBL] [Abstract][Full Text] [Related]
18. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease.
Mahadevan U; Wolf DC; Dubinsky M; Cortot A; Lee SD; Siegel CA; Ullman T; Glover S; Valentine JF; Rubin DT; Miller J; Abreu MT
Clin Gastroenterol Hepatol; 2013 Mar; 11(3):286-92; quiz e24. PubMed ID: 23200982
[TBL] [Abstract][Full Text] [Related]
19. Clinical experience with infliximab and adalimumab in a single-center cohort of patients with Crohn's disease.
Riis A; Martinsen TC; Waldum HL; Fossmark R
Scand J Gastroenterol; 2012 Jun; 47(6):649-57. PubMed ID: 22472026
[TBL] [Abstract][Full Text] [Related]
20. Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial.
Van Assche G; Vermeire S; Ballet V; Gabriels F; Noman M; D'Haens G; Claessens C; Humblet E; Vande Casteele N; Gils A; Rutgeerts P
Gut; 2012 Feb; 61(2):229-34. PubMed ID: 21948942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
